<DOC>
	<DOC>NCT02097277</DOC>
	<brief_summary>The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.</brief_summary>
	<brief_title>A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Diagnosed with type2 diabetes mellitus with HbA1c â‰¥6.5% to less than 10.0% Body mass index 30.0 to 50.0 Any significant acute or chronic medical illness Inability to selfadminister subcutaneous injections Inability to be venipunctured Evidence of organ dysfunction beyond what is consistent with the target population History of allergy to PEGylated compounds or Fibroblast growth factor 21 (FGF21) related compounds</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>